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Androst-5-ene-3b,1 7 b-diol (AED) is an adrenal hormone that has been reported to sustain prostate cancer growth after androgen
deprivation therapy (ADT). LNCaP cells express a mutated androgen receptor that confers the ability to respond not only to
androgen but also to oestrogen and adrenal hormones such as AED, and thus provide a cell line useful for identifying compounds
capable of inhibiting AED-stimulated cell growth. We sought to determine whether structurally related steroids could inhibit
AED-stimulated LNCaP cell growth in vitro and tumour growth in vivo. We report here the identification of a novel androstane
steroid, HE3235 (17a-ethynyl-5a-androstan-3a,1 7 b-diol), with significant inhibitory activity for AED-stimulated LNCaP proliferation.
This inhibitory activity is accompanied by an increase in the number of apoptotic cells. Animal studies have confirmed the
cytoreductive activity of HE3235 on LNCaP tumours. The results suggest that this compound may be of clinical use in castration-
resistant prostate cancer.
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A considerable amount of research has been directed towards
understanding factors that support the growth and expansion of
prostate cancer during and after anti-androgen treatment. The
observation that androgen deprivation results in increase in AR
expression (Scher et al, 2004) highlights the importance of AR in
this stage of disease and suggests that other ligands may be capable
of binding and activating AR to drive tumour cell growth. It is well
documented that mutations in the AR allow castration-resistant
prostate cancer cells to utilise a broad spectrum of steroids, whose
levels are not affected by anti-androgen therapy (Taplin et al,
1995). These include oestrogen, progesterone, glucocorticoid, and
the adrenal hormone androst-5-ene-3b,1 7 b-diol (AED), a multi-
potent hormone that is an androgen and oestrogen precursor, with
the ability to directly transactivate AR and ER in prostate cancer
cells (Miyamoto et al, 1998; Maggiolini et al, 2004).
Because AED’s central role both as a precursor of DHT and a
direct activator of the androgen receptor, we initiated studies to
identify an inhibitor of AED signalling in hormonally sensitive
tumour cells from a proprietary chemical library based on the
structure of AED. Through the course of this work, compounds
were identified that inhibited the proliferation of LNCaP cells
stimulated by AED in vitro. Subsequent work to identify the most
suitable pharmaceutical from this series of compounds resulted in
the identification of HE3235 (17a-ethynyl-5a-androstan-3a,1 7 b-
diol). Here, we present results showing that HE3235 blocks the
growth of LNCaP cells by inducing apoptosis. Tumour studies have
confirmed the in vivo activity of HE3235 against AED-stimulated
LNCaP tumour cells.
MATERIALS AND METHODS
Synthesis of HE3235
HE3235 was synthesised by reacting trimethylsilylazine with
androsterone (DGP, Shanghai, China) in refluxing acetonitrile
using saccharin catalyst. The trimethylsilyl-protected intermediate
was subsequently reacted with ethynyltrimethylsilane activated
with n-butyl lithium in tetrahydrofuran. The crude product was
then recovered by slow addition of water to quench the reaction
and filtration of the crude precipitate. The reaction product was
purified to 499% pure HE3235 with a 67% of overall yield.
LNCaP proliferation assay
LNCaP-FGC, PC3, and DU145 cells were obtained from the
American Type Tissue Collection (ATTC, Manassas, VA, USA).
To identify compounds with anti-proliferative activity for LNCaP,
cells were seeded in poly-D-lysine coated 96-well plates at
3.75 10
4 per ml in a total volume of 200ml of RPMI per 10%
foetal bovine serum (FBS). After incubation overnight at 371C, 5%
CO2, the media was removed and the cells were washed once with
150ml per well of phenol red-free RPMI containing 10% charcoal
per dextran-treated FBS (CS-RPMI) containing 10nM AED.
The appropriate dilution of each test compound was added and
the cells were incubated for 5 days at 371C, 5% CO2. For IC50
determination, a dilution sequence of compound was analysed and
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sthe data were modelled using a nonlinear regression, sigmoidal
dose response, variable slope equation. The curve fit was
constrained with a bottom of 0 and a top of 100. IC50 values were
generated by GraphPad Prism 4. Cell proliferation was measured
on day 5 using the CyQuant assay (Invitrogen, Carlsbad, CA, USA).
The affect of HE3235 on cell growth of LNCaP, PC3, and Du145
cells was assayed by plating 3 10
5cells in 5% CS-RPMI
supplemented with 10nM AED. After 4 days, cells were manually
counted with a haemocytometer.
Apoptosis assay
LNCaP cells (5 10
5) were seeded in phenol red-free RPMI with
5% charcoal-stripped serum (CSS) in 6-well plates and allowed to
adhere overnight, then cultured in CSS supplemented with 10nM
AED with or without 50nM HE3235 for 4 days. At the end of the
incubation period, floating and adherent cells were harvested for
analysis. Apoptosis was measured using the Annexin V-FITC
Apoptosis Detection Kit (Calbiochem, La Jolla, CA, USA)
according to the instructions of the manufacturer to detect
apoptosis. PI and Annexin positive cells were considered
apoptotic.
Androgen-mediated transcription assays
The ARE-luciferase reporter construct (probasin promoter con-
taining ARE) was provided by Dr Plymate (University of
Washington, Seattle, WA, USA), and the 5.8 kb PSA promoter-
luciferase plasmid was provided by Dr Kim (Fred Hutchinson
Cancer Research Center, Seattle, WA, USA). An Amaxa Nucleo-
fector device was used for transfection of LNCaP cells using
solution V and program T-27 according to the manufacturer’s
directions (Amaxa Biosystems Inc., Gaithersburg, MD, USA).
LNCaP cells (1 10
6) were transfected with ARE-reporter plasmid
or PSA-promoter reporter plasmid (1mg). The hTK renilla-
luciferase plasmid (2ng) was transfected under the same condi-
tions to enable normalisation of transfection efficiencies. Cells
were seeded in 24-well plates in phenol red-free RPMI with 5% CSS
to allow adherence overnight, and then DHT, E2, or AED were
added (1nM or 10nM final concentration) with or without 50nM
HE3235 in DMSO. Cells were incubated for B48h, lysed and
subjected to a dual-luciferase assay according to manufacturer’s
recommendations (Promega, Madison, WI, USA) using Tecan
Genios plus luminometer. The luciferace activity was measured
and signal normalised to transfection efficiencies based on TK
transfection.
AED-stimulated LNCaP tumour model
All animal studies were performed within the established IACUC
guidelines. Castrated SCID mice (6 week old) were obtained from
Jackson Laboratories (Bar Harbor, ME, USA). After 4 days of
acclimation, the mice were implanted with AED pellets (5mg, 60-
day time-release, IRA, Sarasota, FL, USA). After 3 days, all mice
were injected subcutaneously in the right flank with 100mlo f
7.5 10
6 LNCaP tumour cells in phenol red-free RPMI mixed 1:1
with Matrigel (BD, Franklin Lakes, NJ, USA). Tumour volumes
were measured weekly and calculated as a
2 b/2 with a being the
width and b the length of the tumour in mm (reported as mm
3).
HE3235 was prepared for injection by dilution in Captisol (CyDex,
Lenexa, KS, USA).
To test the effect of dose on tumour incidence, a total of 48
castrated male SCID mice were implanted with LNCaP tumour
cells as described above, and the mice were randomized into four
groups of 12 animals each (vehicle control, 4mg per mouse per
day, 1mg per mouse per day, and 0.4mg per mouse per day).
Administration of HE3235 (200ml intraperitoneally) or vehicle
began 24h after tumour inoculation. All animals were dosed daily
for 28 consecutive days.
To test the effect of HE3235 on established LNCaP tumours, 36
castrated SCID mice received AED pellets and were implanted with
LNCaP tumour cells and monitored as described above. Once the
tumours reached 15–25mm
3, the mice were paired by tumour
volume, and each mouse in a pair was assigned to either the
vehicle or 4mg per mouse per day HE3235 group. Animals were
dosed IP with 200ml HE3235 or vehicle once a day for 21 days.
Statistical analyses
The incidence of a measurable tumour was estimated as the
relative frequency of mice having a measurable tumour at least
once, any time in the experiment. The significance of the difference
in incidence from vehicle was tested by means of Fisher’s exact
test, adjusted for multiplicity of comparisons (Westfall et al, 1999).
Dose response in the proportion of mice with tumour was tested
for significance through exact Cochran–Armitage test (StatXact
2004). Time to first measurable tumour volume is analysed
through Kaplan–Meier product-limit estimates, with the exact
logrank test applied to test for the significance of the differences
(Cantor, 1997). Tumour volumes and tumour growth rates are
analysed non-parametrically through exact Wilcoxon–Mann–
Whitney test. Resulting P-values are corrected for multiplicity of
comparisons (Westfall et al, 1999).
Reduction of tumour volume refers to a reduction persisting to
the end of the study. Fisher’s exact test was applied to test the
significance of the difference in the incidence of such reduction
relative to vehicle.
Time to first measurable tumour volume is analysed through
Kaplan–Meier product-limit estimates, with the exact logrank test
applied to test for the significance of the difference. Reduction of
tumour volume is defined as a reduction in volume of at least 20%
of the baseline volume, persisting to the end of the study. To detect
the difference between active and control group, Fisher’s exact test
and exact 95% CI for the difference are applied. A tumour of non-
measurable volume is a tumour that, with the methodology at
hand, measures 0 to the end of the study. The growth rate of a
tumour is also analysed through the mixed model.
RESULTS
HE3235 blocks proliferation of LNCaP in vitro
Through titration experiments, a concentration of 10nM AED was
found to provide maximal stimulation of LNCaP, and no
proliferation of LNCaP cells was observed without the addition
of AED (data not shown). Compounds ranked for potency by
titration to calculate the IC50 of the compound. One compound,
HE3235, inhibited LNCaP proliferation in the low nanomolar range
(6nM). This compound reduced LNCaP levels by 60% but had no
inhibitory effect on the AR-negative PC3 and DU145 cells
(Figure 1).
LNCaP tumour model
Treatment with HE3235 resulted in a significant reduction in
tumour incidence (compared with vehicle) in the two highest dose
groups, (40mgkg
 1, P¼0.006, n¼11; 160mgkg
 1, Po0.001,
n¼12), with decreases in tumour volume apparent in all three
dose groups (Figure 2). The mean tumour volume in the animals
that developed tumours were also significantly affected, 157mm
3
(±153) (vehicle) versus 0( Po0.001), 4 (±7) (Po0.001), 34 (±41)
(P¼0.004) mm
3 in the HE3235 treated animals (descending dose).
There was also a statistically significant delay in the time to a
measurable tumour volume in all treated groups (Po0.01) relative
to the vehicle control group.
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sAnti-tumor activity was also observed in animals with
established tumours. As seen in Figure 3, vehicle-treated animals
showed a progressive increase in tumour volume over the course
of the study. In contrast, HE3235 treatment significantly blocked
the growth of tumours (Po0.001). Significant differences in
tumour volumes between the control and treated groups were
observed by the first week and were maintained through the course
of this study (Po0.001). A significantly greater percentage of mice
in the treatment group reduced their tumour volumes by 20% or
more (Po0.03), whereas no tumour reduction was seen in the
vehicle group. Furthermore, tumours in two animals receiving
HE3235 became non-measurable by day 15 of the study.
HE3235 activates the mutant AR in LNCaP and stimulates
PSA secretion
To determine whether HE3235 inhibited the activation of the
LNCaP AR, LNCaP cells were transfected with an ARE and
incubated with HE3235 with or without DHT and AED. As can be
seen in Figure 4, HE3235 did not inhibit the activation of the
LNCaP AR when the cells were stimulated with either DHT or
AED. Instead, HE3235 activated AR in this setting. Consistent with
this finding, an increase in amount of PSA secretion per cell was
observed after incubation with HE3235. PSA rose from 8.5ng per
ml per 10
5cells to 175ng per ml per 10
5cells by day 4 in LNCaP
cells cultures incubated with 50nM HE3235.
HE3235 induces apoptosis in LNCaP
Based on the observations above, the possibility that HE3235 was
affecting cell viability in LNCaP cells was examined. Figure 5 shows
a modest increase (8–21%) in the percentage of apoptotic LNCaP
cells after 4 days of culture with HE3235, suggesting that HE3235 is
cytotoxic for LNCaP cells.
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Figure 2 Dose-dependent effect of HE3235 on AED-stimulated LNCaP
tumour incidence and tumour volume in SCID mice. Grey bars represent
the percentage of animals in each dose group with tumour. Dark bars
represent the average tumour volume (±s.d.).
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Figure 3 Effect of LNCaP of HE3235 on existing AED-stimulated
tumours in SCID mice. LNCaP tumours were established according to
Materials and Methods. Once the tumours reached at least 50mm
3, mice
were separated to treatment (n¼9) and vehicle control (n¼9) groups
and dosed as described in Materials and Methods.
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Figure 4 HE3235 activation of LNCaP AR. LNCaP cells were treated
with 1 or 10nM DHT or AED, charcoal-stripped serum (CSS). The fold
change above background is shown on the y axis.
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Figure 1 LNCaP (’), PC3 (m), and DU145 (E) cells were incubated
with HE3235 at 1nM,1 0 n M, and 50nM and assayed in duplicate for
inhibition of cell growth relative to vehicle as described in Materials and
Methods.
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Figure 5 HE3235 induced apoptosis in LNCaP. The percentage increase
in the number of apoptotic cells after 4 days of incubation with 50nM
HE3235 relative to the vehicle control is represented on the y axis.
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sDISCUSSION
The human prostate cancer cell-line LNCaP expresses a mutant
androgen receptor that allows it to respond to a wide variety of
hormones, including the adrenal hormone AED (Miyamoto et al,
1998; Chang et al, 1999; Mizokami et al, 2004; He and Falany,
2007). Because of its potential role in sustaining prostate cancer
cell growth after androgen deprivation therapy (ADT), we set out
to determine whether a compound capable of inhibiting AED-
stimulated LNCaP cell proliferation could be identified from a
proprietary steroid library that was developed around the structure
of AED. As described here, this library yielded a novel androstane
structure, HE3235, which blocked the proliferation of AED-
stimulated LNCaP cells. This compound had no inhibitory
effect on the AR-negative PC3 and DU145 cells (data not shown),
suggesting that expression of the AR was required for inhibitory
activity. When administered to animals at the time of LNCaP
tumour challenge, HE3235 delayed the onset of the tumours and
reduced tumour volumes in a dose-dependent manner, with a
100% inhibition of LNCaP tumours in the highest dose group.
When treatment was applied to mice with existing tumours, a
reduction in tumour volume was observed by the end of the
first week of treatment, and tumour growth continued to be
depressed throughout the course of the study. In addition, two out
of nine animals treated with HE3235, in this study, had no
detectable tumour volume by the end of the observation period.
These results show that HE3235 had a cytoreductive effect on
tumour volume.
Although the precise mechanism of action of HE3235 still
remains to be elucidated, based on the in vitro and in vivo results
presented here it would appear that HE3235 is not solely blocking
the AED-stimulation of LNCaP tumours, rather, this anti-
neoplastic activity seems to be through the induction of apoptosis.
The exact mechanism through which HE3235 is inducing apoptosis
is unclear. The observation that HE3235 did not inhibit the
proliferation of PC3 and DU145 cells would suggest that the
presence of the AR is required for its activity.
It is well established that DHT can cause a G1 arrest, but not cell
death of LNCaP cells at concentrations above 10
 10nM (Tsihlias
et al, 2000). Based on the results of the ARE studies, an experiment
was conducted to determine whether HE3235 had a similar
cytostatic effect on LNCaP. We also sought to determine whether,
unlike DHT, exposure to HE3235 caused apoptosis in LNCaP cells.
The results of these experiments showed that HE3235 does induce
a modest increase in apoptosis. This finding would be consistent
with the reduction in tumour volumes seen in mice treated with
HE325. These effects are reminiscent of other agents reported to
block the proliferation of prostate cancer cells in vitro and in vivo,
most notable the histone deactylase inhibitors (HDACi). Using the
LNCaP tumour model, sodium butyrate caused G1 cell-cycle arrest,
inhibited LNCaP cell growth and increased PSA gene expression
(Kruh, 1982; Gleave et al, 1998). Similar findings with respect to
inhibition of cell proliferation and PSA secretion have been
reported for vitamin D3 (Esquenet et al, 1996), calcitriol (Bauer
et al, 2003), activin A, (Fujii et al, 2004) and phenylacetate (Walls
et al, 1996). Future work will be directed towards further
understanding whether the molecular mechanism of action of
HE3235 is associated with an HDACi activity.
For many decades, androgen suppression has been the central
theme for treating recurrent prostate cancer, yet virtually no
patients are cured by this therapy. Prostate cancer progresses from
androgen-dependent (AD) tumours that respond favourably to
androgen ablation, to castration-resistant metastatic tumours that
are invariably fatal. Pharmacological methods of lowering andro-
gen levels in patients include the use of hormones that decrease
androgen production, agents that block androgen association with
the androgen receptor, and inhibitors of enzymes involved in
androgen synthesis. Nonetheless, androgen receptor signalling
remains active in castration-resistant prostate cancer despite these
attempts at suppression. There are currently very few treatment
options for men with castration-resistant prostate cancer. Andro-
gen deprivation therapy induces a remission in 80–90% of men
with advanced prostate cancer, and can increase median progres-
sion-free survival by 21 months (Hellerstedt and Pienta, 2002;
Suzuki et al, 2007). This approach eventually fails to stop the
disease progression because prostate tumour cells evolve to a
castration-resistant state, in which tumours develop the ability to
grow in castrate levels of T and DHT at least in part owing to the
presence of AED. As described here, HE3235 represents a therapy
that blocks the growth of AED-stimulated tumour cell growth, and
thus, could be considered as a candidate for the treatment of
castration-resistant prostate cancer.
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